1. Home
  2. IHG vs BBIO Comparison

IHG vs BBIO Comparison

Compare IHG & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercontinental Hotels Group

IHG

Intercontinental Hotels Group

HOLD

Current Price

$143.17

Market Cap

17.0B

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$75.02

Market Cap

15.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHG
BBIO
Founded
1777
2015
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
15.3B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
IHG
BBIO
Price
$143.17
$75.02
Analyst Decision
Hold
Strong Buy
Analyst Count
3
21
Target Price
N/A
$78.81
AVG Volume (30 Days)
247.1K
2.8M
Earning Date
08-02-2016
02-19-2026
Dividend Yield
1.22%
N/A
EPS Growth
21.99
N/A
EPS
4.70
N/A
Revenue
$5,120,000,000.00
$353,780,000.00
Revenue This Year
N/A
$129.14
Revenue Next Year
$6.29
$78.96
P/E Ratio
$29.17
N/A
Revenue Growth
33.89
62.46
52 Week Low
$94.78
$28.33
52 Week High
$144.96
$81.33

Technical Indicators

Market Signals
Indicator
IHG
BBIO
Relative Strength Index (RSI) 58.92 45.15
Support Level $135.70 $76.25
Resistance Level $142.24 $80.00
Average True Range (ATR) 2.53 2.92
MACD 0.34 -0.38
Stochastic Oscillator 87.93 18.26

Price Performance

Historical Comparison
IHG
BBIO

About IHG Intercontinental Hotels Group

InterContinental Hotels Group operates 987,000 rooms across 19 brands addressing the midscale through luxury segments, as of Dec. 31, 2024. Holiday Inn and Holiday Inn Express constitute the largest brand, while Hotel Indigo, Even, Hualuxe, Kimpton, and Voco are newer lifestyle brands experiencing strong demand. The company launched a midscale brand, Avid, in 2017 and closed on a 51% stake in Regent Hotels in 2018. It acquired Six Senses in 2019 and launched another midscale brand, Garner, in 2023. Managed and franchised represent 99% of total rooms. As of Dec. 31, 2024, the Americas represented 53% of total rooms, with Greater China accounting for 20% and Europe, Asia, the Middle East, and Africa making up 27%.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: